The Role of Neuroinflammation in Alzheimer’s Disease

May 10, 2022Henry Peck

Since the discovery of the beta-amyloid peptide in 1984, the amyloid cascade hypothesis has been the primary focus of research surrounding Alzheimer’s disease treatment and is more or less dominating the Alzheimer’s research space. The hypothesis states that the deposition of beta-amyloid protein, the primary component of the plaques, is the causative agent of Alzheimer’s disease pathology and that hallmarks, such as neurofibrillary tangles, cell loss, vascular damage, and dementia, directly result from this deposition.

However, in the past decade, after countless failed clinical trials targeting beta-amyloid plaques, this school of thought is rapidly changing. While beta-amyloid deposition is certainly still a neuropathological hallmark of Alzheimer’s disease and plays a role in the development and progression of Alzheimer’s, it is not the only factor driving Alzheimer’s disease progression. Effective treatment of Alzheimer’s disease will likely rely on a combination of multiple effective therapies targeting different pathological mechanisms. Consequently, a vast range of new novel targets, including neuroinflammation, have entered the clinical research pipeline.

Below, we take a closer look at Alzheimer’s disease neuropathology, the role of neuroinflammation in Alzheimer’s disease, neuroinflammation as a target for treatment, and the shift towards combination treatments for Alzheimer’s.

Alzheimer’s Disease Neuropathology

Neuropathological hallmarks of Alzheimer’s disease consist of positive and negative lesions. Positive lesions include tau hyperphosphorylation, neurofibrillary tangles, beta-amyloid plaques, cerebral amyloid angiopathy, and glial responses, while negative lesions include neuronal and synaptic loss. However, Alzheimer's is most commonly characterized by two core characteristics: beta-amyloid plaques and neurofibrillary tangles resulting from abnormal tau hyperphosphorylation. 

In the past decade, a third core feature of Alzheimer’s has emerged; recent research suggests that chronic neuroinflammation influences beta-amyloid deposition and tau phosphorylation and may contribute to accelerated Alzheimer’s disease progression. In several other studies, it has also been proposed that the inflammatory response may link the initial beta-amyloid pathology and the later development of neurofibrillary tangles.

Neuroinflammation in Alzheimer’s Disease

Acute inflammation in the brain is a normal defense against toxins, infections, and injury; however, in Alzheimer’s disease, there is a disruption in the equilibrium of anti- and pro-inflammatory signals, which can result in chronic neuroinflammation, the hallmark of dysregulated microglia.

Consequently, chronic neuroinflammation in Alzheimer’s disease is believed to be primarily attributed to activated microglial cells and the release of cytokines. Chronic neuroinflammation was previously thought to be a result of the neuronal loss that occurs in Alzheimer’s. However, a significant amount of research suggests that this sustained immune response in the brain is an early event in the Alzheimer’s disease continuum and neuroinflammation is a central mechanism that facilitates and exacerbates beta-amyloid and tau pathologies in addition to contributing to neurodegeneration. Depending on the state of the disease, activated microglia may have diverse impacts on the progression of Alzheimer’s disease.

It should be noted that neuroinflammation is not unique to Alzheimer’s disease; numerous studies have demonstrated elevated markers of inflammation in the brains of those with Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis. Additionally, inflammatory pathways for Alzheimer’s are quite similar to those for diabetes. This is why drugs like semaglutide are often repurposed for Alzheimer’s disease.

The Path Towards Precision Medicine in Alzheimer’s Disease Treatment

As chronic neuroinflammation in Alzheimer’s disease may accelerate other core pathologies, inflammatory mechanisms appear to be viable targets for therapeutic development, alongside established targets, such as beta-amyloid and tau, and new targets, such as mitochondria and metabolic dysfunction, vascular disease, synaptic activity and neurotransmitters, and genetics and epigenetics.

The complex pathology of Alzheimer’s disease will likely necessitate combination treatments rather than monotherapy. Because every individual’s neurocognitive domain functions are affected uniquely in the presence of Alzheimer’s, the treatment pathways will also likely be unique. Utilizing multiple effective treatments tailored to an individual’s specific impairments due to their unique pathological manifestations will allow for more effective, well-rounded, and personalized treatment.

Altoida: Pioneering Precision Neurology to Drive Precise, Personalized Treatment

At Altoida, we are building the world’s-first Precision Neurology platform and app-based medical device—backed by 11 years of clinical validation—to accelerate and improve drug development, neurological disease research, and patient care.

By completing a 10-minute series of augmented reality and motor activities designed to simulate complex Activities of Daily Living on a smartphone or tablet, Altoida’s device extracts and provides robust measurements of neurocognitive function across 13 neurocognitive domains. Our device measures and analyzes nearly 800 multimodal cognitive and functional digital biomarkers. Through the collection of highly granular data from integrated smartphone or tablet sensors, Altoida’s device produces comprehensive neurocognitive domain scores. 

This method, along with our innovative artificial intelligence, will pioneer fully digital predictive neurological disease diagnosis. After our Breakthrough Device designation by the FDA, Altoida’s device will provide patients with a predictive score that will enable a highly accurate prediction of whether a patient aged 55 and older will or will not convert from Mild Cognitive Impairment to Alzheimer’s disease.

 When this score is taken in conjunction with our neurocognitive domain scores, providers will be able to make specific, personalized conclusions about how neurological diseases are uniquely affecting their patients. This in turn will enable a personalized precision approach to treatment and care plan development for neurological disease patients.

To learn more about neuroinflammation in Alzheimer’s disease or about utilizing Altoida’s Precision Neurology platform and medical device, contact us today.

Contact Us

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.
Contact Us

Contact Us

80 M Street SE, Suite 100 Washington, DC 20003 USA 

CONTACT@ALTOIDA.COM

Follow Us

Policy

By visiting our Website and/or using the Services in any manner, you acknowledge that you accept the practices and policies outlined in our Privacy Policy.
@ Altoida 2021